Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
04:43pm, Monday, 22'nd Jun 2026
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
04:01pm, Thursday, 14'th May 2026
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 13'th May 2026
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
04:01pm, Wednesday, 13'th May 2026
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
05:20pm, Monday, 11'th May 2026
•MacroGenics to receive $122. 5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD,
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
05:20pm, Monday, 11'th May 2026
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
11:00am, Tuesday, 05'th May 2026
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
07:30am, Monday, 04'th May 2026
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGe
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study
04:30pm, Wednesday, 08'th Apr 2026
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenic
MacroGenics (NASDAQ:MGNX) & Medtronic (NYSE:MDT) Critical Review
01:09am, Monday, 06'th Apr 2026
Medtronic (NYSE: MDT - Get Free Report) and MacroGenics (NASDAQ: MGNX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:12pm, Thursday, 12'th Mar 2026
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
06:15pm, Monday, 09'th Mar 2026
MacroGenics (MGNX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.25 per share a year ago.
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
04:01pm, Monday, 09'th Mar 2026
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the tre
MacroGenics to Participate in Upcoming Investor Conferences
05:30pm, Thursday, 26'th Feb 2026
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
06:14pm, Monday, 23'rd Feb 2026
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer
